QUETIAPINE SANDOZ 150 MG PRT

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

QUETIAPINE AS FUMARATE

Disponibbli minn:

NOVARTIS ISRAEL LTD

Kodiċi ATC:

N05AH04

Għamla farmaċewtika:

TABLETS PROLONGED RELEASE

Kompożizzjoni:

QUETIAPINE AS FUMARATE 150 MG

Rotta amministrattiva:

PER OS

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

SALUTAS PHARMA GMBH, GERMANY

Żona terapewtika:

QUETIAPINE

Indikazzjonijiet terapewtiċi:

Quetiapine Sandoz PRT is indicated for the treatment of Schizophrenia. Quetiapine Sandoz PRT is effective in preventing relapse in stable schizophrenic patients who have been maintained on Quetiapine Sandoz PRT. Quetiapine Sandoz PRT is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate. Quetiapine Sandoz PRT is indicated for the treatment of major depressive episodes in bipolar disorder. Quetiapine Sandoz PRT is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. Quetiapine Sandoz PRT is indicated for add-on treatment of major depressive episods in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy . Prior to initiating treatment, clinicians should consider the safety profile of Quetiapine Sandoz PRT.

Data ta 'l-awtorizzazzjoni:

2020-11-30

Fuljett ta 'informazzjoni

Artwork Order No.:
Artwork Order description:
AW identifier No. New:
Proof No.:
Dimension:
Tech. Drawing No.:
Live text:
Condensed font:
Font type:
Creation date:
Artwork creator:
Braille:
Printing colours:
Technical colours:
Print enhancements:
AW identifier No. Old:
Packaging site:
Minimum font size body text:
Variable data prefixes font size:
!
P L E A S E
T U R N
O V E R P R I
N T I
N G
O N
!
50096899_2828380/2-IL
X
300020769
50088216
170 X 900 MM
Yes No Both
Artwork Service Provider
Black
Yes No
Arial
7 pt
Nurit Assayag
19/09/22
LF QUETIAPINE SDZ 50MG PRT IL
1
X
DOR
QUETIAPINE_TABS_SANDOZ_IL_
(UHL)_LEAFLET_2828380-2_
20220506081752.pdf
CM, GR, RODOPI, PHARMATHEN INTERNATIONAL SA (SZ ESO HUB)
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS )PREPARATIONS( –
986
The medicine is dispensed with a doctor’s prescription only
QUETIAPINE SANDOZ
®
50 MG PRT
PROLONGED RELEASE TABLETS
COMPOSITION:
Each tablet contains
quetiapine )as fumarate( 50 mg
QUETIAPINE SANDOZ
®
150 MG PRT
PROLONGED RELEASE TABLETS
COMPOSITION:
Each tablet contains
quetiapine )as fumarate( 150 mg
QUETIAPINE SANDOZ
®
200 MG PRT
PROLONGED RELEASE TABLETS
COMPOSITION:
Each tablet contains
quetiapine )as fumarate( 200 mg
QUETIAPINE SANDOZ
®
300 MG PRT
PROLONGED RELEASE TABLETS
COMPOSITION:
Each tablet contains
quetiapine )as fumarate( 300 mg
QUETIAPINE SANDOZ
®
400 MG PRT
PROLONGED RELEASE TABLETS
COMPOSITION:
Each tablet contains
quetiapine )as fumarate( 400 mg
Inactive
ingredients
and
allergens:
see
section
2
sub-section
“Important information about some of the ingredients of the
medicine”
and section 6 “Further information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE.
This leaflet contains concise information about this medicine. If
you have any further questions, consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not
pass it on to others. It may harm them, even if it seems to you that
their illness is similar to yours.
The medicine is not int